Username:
Password:
Forgot Password?
Remember me
Decade: 2010-2010 2000-2009 1990-1999 1980-1989 1970-1979
Year: 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000
Issues: Vol. 102 No. 12 December 22, 2008 p.1L-50L-Supplement Vol. 102 No. 12 December 15, 2008 p.1577-1746 Vol. 102 No. 11 December 1, 2008 p.1427-1576 Vol. 102 No. 10 November 17, 2008 p.1K-36K-Supplement Vol. 102 No. 10 November 15, 2008 p.1285-1426 Vol. 102 No. 9 November 3, 2008 p.1J-38J-Supplement Vol. 102 No. 9 November 1, 2008 p.1119-1284 Vol. 102 No. 8 October 15, 2008 p.957-1118 Vol. 102 No. 8 October 12, 2008 p.1I-270I-Supplement Vol. 102 No. 7 October 1, 2008 p.797-956 Vol. 102 No. 6 September 22, 2008 p.1H-32H-Supplement Vol. 102 No. 6 September 15, 2008 p.649-796 Vol. 102 No. 5 September 8, 2008 p.1G-68G-Supplement Vol. 102 No. 5 September 1, 2008 p.509-648 Vol. 102 No. 4 August 15, 2008 p.375-508 Vol. 102 No. 3 August 1, 2008 p.249-374 Vol. 102 No. 2 July 15, 2008 p.115-248 Vol. 102 No. 1 July 1, 2008 p.1-114 Vol. 101 No. 12 June 16, 2008 p.S1-S2-Supplement Vol. 101 No. 12 June 15, 2008 p.1683-1810 Vol. 101 No. 11 June 2, 2008 p.S1-S116-Supplement Vol. 101 No. 11 June 1, 2008 p.1523-1682 Vol. 101 No. 10 May 22, 2008 p.S1-S86-Supplement Vol. 101 No. 10 May 15, 2008 p.1373-1524 Vol. 101 No. 9 May 1, 2008 p.1219-1372 Vol. 101 No. 8 April 23, 2008 p.S1-S108-Supplement 2 Vol. 101 No. 8 April 17, 2008 p.S1-S62-Supplement Vol. 101 No. 8 April 15, 2008 p.1073-1218 Vol. 101 No. 7 April 1, 2008 p.911-1072 Vol. 101 No. 6 March 15, 2008 p.747-910 Vol. 101 No. 5 March 1, 2008 p.557-746 Vol. 101 No. 4 February 15, 2008 p.419-556 Vol. 101 No. 3 February 4, 2008 p.S1-S96-Supplement Vol. 101 No. 3 February 1, 2008 p.279-418 Vol. 101 No. 2 January 15, 2008 p.139-278 Vol. 101 No. 1 January 1, 2008 p.1-138
Niacin Therapy: An Evolving Paradigm for the Management of Mixed Dyslipidemia and Low High-Density Lipoprotein Cholesterol
Edited by Michael H. Davidson MD, Christie M. Ballantyne MD
Publication of these proceedings was supported by an unrestricted educational grant from Abbott Pharmaceuticals.
Search Within This Issue
13 Articles:
The authors who contributed to this publication have disclosed the following industry relationships:
Niacin, or nicotinic acid, is a potent lipid-modifying agent with broad-spectrum effects, including reductions in low-density lipoprotein (LDL) cholesterol, triglyceride, and lipoprotein(a) levels and...
Niacin is the most potent lipid-altering agent for raising high-density lipoprotein (HDL) cholesterol levels. Niacin also lowers triglyceride (TG) levels, lowers low-density lipoprotein (LDL) choleste...
Of currently approved drugs, niacin is the most effective in raising high-density lipoprotein cholesterol levels, either as monotherapy or in combination with other agents. The US Food and Drug Admini...
Niacin, or nicotinic acid, has established efficacy for the treatment of dyslipidemia, but the clinical use of niacin has been limited by cutaneous flushing, a well-recognized associated adverse effec...
Nicotinic acid (niacin) has long been used for the treatment of lipid disorders and cardiovascular disease. Niacin favorably affects apolipoprotein (apo) B–containing lipoproteins (eg, very-low-densit...
Combination therapy for patients with coronary artery disease (CAD) is often indicated as a significant number of patients receiving 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) ...
High-density lipoprotein (HDL) is a “regression particle” based on its unique lipid particle biology. This unique property predicts that, in theory, therapies that raise HDL cholesterol should be able...
Over the years, niacin has gained recognition as an atheroprotective agent, in part because of its capacity to lower the plasma levels of cholesterol, triglycerides, and very-low- and low-density lipo...
Five lines of evidence justify comprehensive lipoprotein management over aggressive low-density lipoprotein (LDL) lowering alone in most cases of cardiovascular disease (CVD) prevention. First, lipopr...
The current guidelines for the treatment of high risk lipid disorders do not specify a therapeutic target level of high-density lipoprotein (HDL) cholesterol for cardiovascular disease prevention in h...
